Abstract:Background: EGFR mutation is a strong predictor of efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) therapy in advanced non-small cell lung cancer (NSCLC). However, around 20-30 % of EGFR-mutated cases showed no response to EGFR-TKIs, suggesting that other determinants beyond EGFR mutation likely exist. This study analyzed the role of microRNAs (miRNAs) in primary resistance to EGFR-TKIs in advanced NSCLC patients with EGFR mutation.Methods: Training group: 20 advanced NSCLC patients with EGFR 19 deletion treated with first-line EGFR-TKIs were enrolled; half of them had dramatic responses while the other half had primary resistance. Matched plasma samples were collected for miRNA profiling using TaqMan low-density array (TLDA). Bioinformatics analyses were used to identify related miRNAs possibly accounted for resistance. Testing group: Quantitative reverse transcriptase PCR (qRT-PCR) was employed to detect the level of miRNA with significant differential expression in the training set. Validation group: Another cohort with EGFR 19 deletion mutations, who had dramatically different responses to EGFR-TKI, was used to validate the difference of miRNA expression between the sensitive and resistant groups using RT-PCR.Results: Training group: 153 miRNAs were found to be differentially expressed between the sensitive and resistant groups. Potential target genes were predicted with a target scan database. Twelve differentially expressed miRNAs were selected for the analysis because of their known roles in tumorigenesis of lung cancer, resistance to drugs, and regulation of EGFR pathway. Training group: three out of the 12 miRNAs (miR-21, AmiR-27a, and miR-218) were verified to have significantly higher expression (PmiR-21 = 0.004, PmiR-27a = 0.009, PmiR-218 = 0.041, respectively) in the resistant group compared to the sensitive group. Validation group: The expression levels of these three miRNAs were validated to be significantly different (P = 0.011, 0.011, 0.026, respectively) in the validation cohort (n = 34).Conclusions: Higher expression levels of miR-21, AmiR-27a, and miR-218 detected in this study suggest potential roles of these miRNAs in primary resistance to EGFR-TKI in advanced NSCLC patients with EGFR exon 19 deletion mutations. These findings need to be further confirmed in a study with a larger sample size.

The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer

miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential

The Roles of Micrornas in Regulating Chemotherapy Resistance of Non-Small Cell Lung Cancer.

Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer.

Micrornas Associated With Therapy Of Non-Small Cell Lung Cancer

Role Of Microrna In Anticancer Drug Resistance

Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer

Effects of Microrna Regulation on Antiangiogenic Therapy Resistance in Non-Small Cell Lung Cancer.

Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer

Research progress on the relationship between lung cancer drug-resistance and microRNAs

MicroRNAs in non‐small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential

The role and mechanisms of action of microRNAs in cancer drug resistance

Role of Micrornas on Therapy Resistance in Non-Hodgkin's Lymphoma.

MicroRNAs As Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer

Function of Mirna in Controlling Drug Resistance of Human Cancers

MicroRNA-targeted therapeutics for lung cancer treatment

MiRNA-based therapeutic strategy in lung cancer.

Identification of Plasma Microrna Profiles for Primary Resistance to EGFR-TKIs in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Activating Mutation.

Comprehensive review of LncRNA-mediated therapeutic resistance in non-small cell lung cancer

Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives

Long non-coding RNAs in non-small cell lung cancer: implications for EGFR-TKI resistance